Amplified centrosomes in breast cancer: A potential indicator of tumor aggressiveness

Breast Cancer Research and Treatment

Volumn 75, Issue 1, 2002, Pages 25-34

  D'Assoro, Antonino B ^a   Barrett, Susan L ^a   Folk, Christopher ^a   Negron, Vivian C ^a   Boeneman, Kelly ^a   Busby, Robert ^a   Whitehead, Clark ^a   Stivala, Franca ^b   Lingle, Wilma L ^a   Salisbury, Jeffrey L ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Aneuploidy; Estrogen receptor; Microtubules; Mitotic spindle; p21Waf1 Cip1; p53

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53;

ANEUPLOIDY; ARTICLE; BREAST CANCER; CENTROSOME; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MITOSIS SPINDLE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; BREAST TUMOR; CANCER INVASION; CARCINOMA; CELL CULTURE; DISEASE COURSE; GENETICS; PATHOLOGY; PREDICTION AND FORECASTING;

BREAST NEOPLASMS; CARCINOMA; CENTROSOME; DISEASE PROGRESSION; HUMAN; MITOTIC SPINDLE APPARATUS; NEOPLASM INVASIVENESS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; HUMANS;

EID: 0036707708     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016550619925     Document Type: Article

References (51)

1. Genetic instabilities in human cancers
2. A mutator phenotype in cancer
3. Developmental, cellular, and molecular basis of human breast cancer
4. Estrogen receptor expression in benign breast epithelium and breast cancer risk
5. Molecular pathology of breast carcinoma
6. Managing the centrosome numbers game: From chaos to stability in cancer cell division
7. Centrosome hyperamplification in human cancer: Chromosome instability induced by p53 mutation and/or Mdm 2 overexpression
8. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations
9. Centrosome hypertrophy in human breast tumors: Implications for genomic stability and cell polarity
10. Centrosome defects and genetic instability in malignant tumors
11. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
12. Human Papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype
13. Abnormal centrosome amplification in the absence of p53
14. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model
15. Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: Evidence for a gain of function
16. Requirement of a centrosomal activity for cell cycle progression through G1 into S phase
17. Cyclin-dependent kinase control of centrosome duplication
18. p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells
19. Identification of CIP-1-associated regulator of cyclin B (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle
20. Genomic instability in Gadd45a-deficient mice
21. Altered centrosome structure is associated with abnormal mitoses in human breast tumors
22. Methods for the analysis of centrosome reproduction in cancer cells
23. Microtubule nucleating capacity of centrosomes in tissue sections
24. The relationship of HsEg5 and the actin cytoskeleton to centrosome separation
25. Centrosome amplification drives chromosomal instability in breast tumor development
26. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma
27. Chromosome-specific aneusomy in carcinoma of the breast
28. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine
29. Denaturing high performance liquid chromatography (DH-PLC) used in the detection of germline and somatic mutations
30. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
31. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
32. Normal p53 status and function despite the development of drug resistance in human breast cancer cells
33. Metastasis from human breast cancer cell lines
34. In vitro models
35. Establishment and characterization of a cell line of human breast carcinoma origin
36. A human cell line from a pleural effusion derived from a breast carcinoma
37. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer
38. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients
39. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors
40. DNA index, S-phase fraction, histological grade and prognosis in breast cancer
41. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts
42. BRCA1 is associated with the centrosome during mitosis
43. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A
44. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression
45. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells
46. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification
47. Molecular targets for breast cancer therapy and prevention
48. Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells
49. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression
50. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
51. Deregulation of cyclin E in breast cancer